CANINE ATOPIC DERMATITIS TREATMENT DRUGS MARKET ANALYSIS

Canine Atopic Dermatitis Treatment Drugs Market, By Drug Class (Janus Kinase Inhibitors, Antihistamines, Monoclonal Antibodies, Antibiotics, Allergic Immunotherapy/Desensitization Therapy, and Others), By Route of Administration (Injectable, Oral, and Topical), By Dosage Form (Tablets, Creams, Spray, and Others), By Distribution Channel (Online and Offline), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Apr 2024
Code : CMI4886
Pages :165
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Canine Atopic Dermatitis Treatment Drugs Market Regional Insights

To learn more about this report, request sample copy

North America remains the dominant region in the global canine atopic dermatitis treatment drugs market and is anticipated to hold 41.1% of the market share in 2024 owing to a strong presence of leading manufacturers in the region. The U.S. accounts for the largest share primarily due to high pet adoption and high expenditure on pet healthcare. Pet owners in the U.S. are increasingly willing to spend on premium drugs for atopic dermatitis treatment of their dogs. Further, awareness regarding atopic dermatitis is also higher among pet owners in the country driving the sales of prescription drugs. Leading pharmaceutical companies such as Zoetis, Elanco, and Virbac have established their bases in the U.S. to cater to the growing demand. The Europe canine atopic dermatitis treatment drugs market is currently the fastest growing regional market globally. Germany holds the largest share within Europe owing to high number of companion animal practices and increasing pet healthcare expenditure. Countries including France, Italy, and the U.K. are also lucrative markets contributing to Europe's overall growth. Higher pricing of drugs is supporting the market growth in monetary terms. Growing number of atopic dermatitis cases in dogs is facilitating the demand for effective treatment options. In addition, supportive regulatory environment and rapid product approvals provide impetus to local pharmaceutical players to launch innovative therapies in the region.